One Biosciences
Description
One Biosciences uses cutting-edge single-cell technologies and AI to provide high-resolution omics profiling for patient selection, development of novel therapies, optimal treatment strategies and clinical trial matching. More of a techbio play, positioning the company to create significant value rapidly: by 2025, we aim to fine-tune our molecular profiling approach through pilot studies, while forging R&D partnerships with pharmaceutical and biotech companies. Our goal is to continue setting the bar in single-cell profiling for clinical applications and make it an attractive asset for some of the large players (Tempus, Vanguard…ect…) and US investors.
Company members
Hedi Ben Brahim ; David Schilansky